Bifidobacterium longum BORI inhibits pain behavior and chondrocyte death, and attenuates osteoarthritis progression
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0286456 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Dong Keon Oh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Cartilage, Articular, Osteoarthritis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Assembly.
Abstract (Originalsprache)
Osteoarthritis (OA), the most common form of arthritis, is characterized by pain and cartilage damage; it usually exhibits gradual development. However, the pathogenesis of OA remains unclear. This study was undertaken to improve the understanding and treatment of OA. OA was induced in 7-week-old Wistar rats by intra-articular injection of monosodium iodoacetate (MIA); subsequently, the rats underwent oral administration of Bifidobacterium longum BORI ( B . BORI). The effects of B . BORI were examined in chondrocytes and an MIA-induced OA rat model. In the rats, B . BORI-mediated effects on pain severity, cartilage destruction, and inflammation were recorded. Additional effects on mRNA and cytokine secretion were analyzed by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay. Paw withdrawal threshold, paw withdrawal latency, and weight-bearing assessments revealed that pain severity in MIA-induced OA rats was decreased after B . BORI treatment. Histopathology analyses and three-dimensional surface renderings of rat femurs from micro-computed tomography images revealed cartilage protection and cartilage loss inhibition effects in B . BORI-treated OA rats. Immunohistochemical analyses of inflammatory cytokines and catabolic markers (e.g., matrix metalloproteinases) showed that the expression levels of both were reduced in tissue from B . BORI-treated OA rats. Furthermore, B . BORI treatment decreased the expression levels of the inflammatory cytokine monocyte chemoattractant protein-1 and inflammatory gene factors (e.g., inflammatory cell death markers) in chondrocytes. The findings indicate that oral administration of B . BORI has therapeutic potential in terms of reducing pain, progression, and inflammation in OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Korea.
- Research Center, BIFIDO Co., Ltd., Hongcheon, South Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea.
ORCID-Profile: Mi-La Cho, Sung-Hwan Park
Förderung
- National Assembly
Zitieren
APA
Oh, D. K., Na, H. S., Jhun, J. Y., Lee, J. S., Um, I. G., Lee, S. Y., Park, M. S., Cho, M. L., & Park, S. H. (2023). Bifidobacterium longum BORI inhibits pain behavior and chondrocyte death, and attenuates osteoarthritis progression. PLOS ONE. https://doi.org/10.1371/journal.pone.0286456
Vancouver
Oh DK, Na HS, Jhun JY, Lee JS, Um IG, Lee SY, et al. Bifidobacterium longum BORI inhibits pain behavior and chondrocyte death, and attenuates osteoarthritis progression. PLOS ONE. 2023. doi:10.1371/journal.pone.0286456
BibTeX
@article{Oh2023,
author = {Oh, Dong Keon and Na, Hyun Sik and Jhun, Joo Yeon and Lee, Jeong Su and Um, In Gyu and Lee, Seung Yoon and Park, Myeong Soo and Cho, Mi-La and Park, Sung-Hwan},
title = {Bifidobacterium longum BORI inhibits pain behavior and chondrocyte death, and attenuates osteoarthritis progression},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0286456}
}
EUVIMED